Sever drug classes acting on various targets like multikinase inhibitors, MET receptor inhibitor, angiogenesis inhibitors and mTOR inhibitors have shown efficacy in the treatment of HCC patients. This evidence concerns the gene MTOR and hepatocellular carcinoma.